02 8011 4217, 0416 974 651  info at scenar.com.au

SCENAR-technology for chemotherapy-induced neurotoxicity

Abstracts of the 20th Anniversary International MASCC/ISOO Symposium

Support Care Cancer (2007) 15:651–797 DOI 10.1007/s00520-007-0262-7

SCENAR-technology for chemotherapy-induced neurotoxicity
B. Zaidiner1, N. Lyan2, I. Baranovsky3, I. Petrenko4 1Regional Cancer Hospital, Department of Ambulatory Care, Rostov-on-Don, Russia 2Medical Unit BIOCAR, Rostov-on-Don 3Medical Unit “Zdorov’e”, Rostov-on-Don 4Pharmacy Unit, Rostov-on-Don

Background: Drug toxicity is the major limiting factor in chemotherapy (CT) of malignancies. Anti-cancer agents produced a broad range of side effects that diminish patients’ quality of life and limit their ability to tolerate the pIanned treatment regimen. The supportive care for these patients is routinely based on chemoprotectants: mesna, amifostine etc., the physical factors in this context are less common.

Our previous works have shown the efficacy of SCENARdevice (US Patent 1 5257623) for pain relief and some other issues. We’ve tried to present our experience in usage of SCENAR-technology for CT-induced neurotoxicity.

Materials and methods: In this preliminary trial 36 pts (mean age 46.8±7.6 years) with advanced ovarian cancers were observed. All patients were treated with Pt derivatives (oxaliplatin, cisplatin), whose cumulative dose have being ?540 mg/m*; they suffered from burning & aching pains and paresthesias; sensory deficit was noted. After signing the informed consent every patient 15 SCENAR-procedures were done in addition to conventional supportive therapy. These procedures consisted of treatment of various cutaneous areas which were chosen as applied patient’s complaints. They were conducted daily, their technique was described earlier.

Results: We’ve achieved positive results in 23 patients (63.9%) who felt better, their pain relief ratings on Visual Analogue Scale were significantly improving, part of them could refuse or reduce analgesic usage), the sensory disturbances were partially restored. The reasonable results were noted in 8 (22.2%) and bad in 5 (13.9%) patients. The analgesic reducing helped to prevent their side-effects.

Conclusion: SCENAR may be useful for patients with  anticancer toxicity as a part of comprehensive therapeutic program. Its exact position in variety of clinical situations will be established in the randomized placebo-controlled trial which is being conducted now. We conceive our results to be promising for continued study of SCENAR technology in supportive care.